Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 15 results for omalizumab

  1. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

  2. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

  3. Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)

    NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA678

  4. Reslizumab for treating severe eosinophilic asthma (TA479)

    Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.

  5. Tezepelumab for treating severe asthma (TA880)

    Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.

  6. 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]

    In development [GID-TA11355] Expected publication date: 12 February 2025

  7. The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma

  8. CT-P39 (omalizumab biosimilar) for previously treated chronic spontaneous urticaria TS ID 11832

      Status ...

  9. Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)

    NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma

  10. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

    Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.

  11. Past appeals and decisions

    TA ID Appraisal Short title TA201 Asthma (in children) - omalizumab TA265 Bone metastases from solid tumours - denosumab TA566

  12. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  13. Omalizumab for severe persistent allergic asthma (TA133)

    This guidance has been replaced by NICE technology appraisal guidance 278.

  14. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.

  15. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)

    This guidance has been updated and replaced by NICE technology appraisal guidance 278.